Neurotherapeutics for non-psychiatric disorders present what may be the greatest field of unmet need in medicine. They have been significantly underdiagnosed and vastly underserved for a number of reasons. Certain neurological disorders, such as peripheral neuropathies, are secondary to other conditions, which overshadow the neuropathy. In addition, CNS conditions are frequently undiagnosed or unrecognized because their symptoms may not cause sufficient concern in the patient or may be confused with those of other conditions by the clinician. As a result, the incidence and prevalence of the CNS diseases and disorders that are not seriously debilitating or fatal are significantly underestimated.
However, this unmet need represents a burgeoning opportunity for a new generation of therapeutics. The range of conditions requiring new treatments vary from minor symptoms to completely debilitating and even fatal diseases such as multiple sclerosis and Parkinsons disease. New understandings of genetics are promising early identification of sufferers for conditions caused by inborn errors of metabolism, and although many of these disorders are rare, and may qualify as "orphan diseases" under current law, many share similar underlying mechanisms, opening the possibility of expanded markets for these new treatments.
Until the 1990s, the vast majority of therapeutics for neurological diseases and disorders were palliative. With the rapidly increasing understanding of the nature of the nervous system, its interactions with muscles and other organs, and the cell biology of nerve cells, newer therapeutics are addressing root causes of neurological problems. Small biopharmaceutical companies are leading the way in advances in modern neurotherapeutics. The number of such companies, focused on neurotherapeutics, has increased significantly in the past five years and may be expected to increase further during the near term.
Kalorama’s new study looks at the worldwide market and market potential for drugs to treat these widely varying, but deadly similar diseases. The report covers the unmet need and commercial outlook for such conditions as:
The study reviews current therapeutic approaches as well as forward-looking technologies, such as biological therapy, immunotherapy, and gene therapy. The study also provides a complete competitive and strategic analysis and overview of regulatory and clinical trends.
Unmet Need and Research Innovation Drive $70+ Billion Neurotherapeutics Market
New York, July 30, 2002 /PR Newswire — Unmet need and ballooning incidence are teaming up to create huge market potential in neurological drugs, according to a new market study released today from Kalorama Information. The world market stands at $70 billion in 2002, according to the study, but steady growth in demand and product introduction will result in markets in excess of $88 billion by 2010.
The study, entitled The World Market for Neurotherapeutic Drugs, revealed several surprising findings. For example, while neurological cancer presents the largest defined segment of neurotherapeutics at the moment, the largest area of opportunity is that for peripheral neuropathies, which has been hindered in its development by lack of definition and failure to diagnose. The market potential for pharmaceuticals in the treatment of peripheral neuropathies represents $15 billion in the seven major world healthcare markets. This market potential is growing at the compound annual rate of 6.3%.
"The status of the market in terms of revenues is misleading of the potential market as a whole," points out Kenneth Krul, Ph.D., the author of the report. "It does not allow for the understanding of the potential of unmet need. The vast majority of current drugs are merely palliative; hence, the current market does not reflect the true potential of the neurological therapeutics markets."
The study thoroughly reviews market potential, research initiatives, and product commercialization across the entire spectrum of non-psychiatric neurological disease, including Alzheimer’s disease, amyotrophic lateral sclerosis, brain and spinal cord injury, cognition disorders, epilepsy, insomnia, multiple sclerosis, neurological cancers, Parkinson’s disease, peripheral neuropathy, and stroke. The study encompasses the top seven world markets: the United States, France, Germany, Italy, Japan, Spain, and the United Kingdom.
About Kalorama Information
Kalorama Information, an imprint of MarketResearch.com, supplies the latest in market research for the life sciences. For more information visit us at www.KaloramaInformation.com or contact Steven Heffner at 212-807-2634 or email@example.com.
MarketResearch.com is the leading provider of global market intelligence products and services. With over 50,000 research publications from 350 research publishers, they offer instant online access to the world’s most extensive database of expert insights on global industries. Updated daily. For more information, contact Kim Bolus at 212-807-2655 or firstname.lastname@example.org.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook